Diego Maselli Caceres, MD
Pulmonary Disease · San Antonio, TXNPI 1609000421
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,031,583 of the $1,547,264 with a category attached, or 66.7%. 35 manufacturers reported payments, led by AstraZeneca at 34.2% of the total. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,249 payments — averaging $1238.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$530K
- GSK$318K
- Sanofi$281K
- Regeneron Healthcare Solutions, Inc.$230K
- Insmed, Inc.$63K
- Sanofi-aventis U.S. LLC$29K
- plus $98K from 29 others
Across 63 payments — averaging $4665.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$188K
- Astrazeneca AB$73K
- F. Hoffmann-la Roche AG$8K
- Novartis$8K
- Astrazeneca UK Limited$6K
- Sanofi$4K
- plus $6K from 2 others
What the payments were for
- Consulting fees$356,71423%
- Speaking & faculty fees$1,031,58367%
- Travel & lodging$129,1348%
- Food & beverage$29,5332%
- Education$2830%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 489 | $529,529 |
| GSK | 253 | $317,787 |
| Sanofi | 138 | $280,669 |
| Regeneron Healthcare Solutions, Inc. | 189 | $229,559 |
| Insmed, Inc. | 42 | $62,629 |
| Sanofi-aventis U.S. LLC | 10 | $29,000 |
| Amgen | 31 | $27,228 |
| Sunovion Pharmaceuticals Inc. | 18 | $18,576 |
| Regeneron | 12 | $13,931 |
| Boehringer Ingelheim | 9 | $9,259 |
| Genentech USA, Inc. | 9 | $8,274 |
| Zambon USA Ltd. | 4 | $5,803 |
| Novartis | 4 | $4,956 |
| Pfizer | 2 | $2,500 |
| Mylan Specialty L.p. | 1 | $2,394 |
| Verona Pharma, Inc. | 1 | $2,100 |
| Electromed, Inc. | 3 | $1,259 |
| Viiv Healthcare Company | 1 | $600 |
| Merck | 9 | $209 |
| United Therapeutics Corporation | 1 | $150 |
| Viatris Specialty LLC | 1 | $125 |
| Exthera Medical Corporation | 2 | $124 |
| Pulmonx Corporation | 1 | $122 |
| Inari Medical, Inc. | 1 | $100 |
| Actelion Pharmaceuticals US, Inc. | 3 | $73 |
| Johnson & Johnson | 2 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Genentech, Inc. | 1 | $44 |
| Mayne Pharma Commercial LLC | 2 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $18 |
| Shionogi Inc | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $17 |
| Chiesi USA, Inc. | 1 | $15 |
| 3b Medical, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$504,194
- NUCALA$173,256
- TEZSPIRE$163,820
- FASENRA$147,026
- BREZTRI$99,790
- AIRSUPRA$78,739
- TRELEGY ELLIPTA$46,187
- LONHALA MAGNAIR$18,363
- ANORO$8,047
- STIOLTO RESPIMAT$3,450
- BREZTRI AEROSPHERE$3,025
- Yupelri$2,519
- Ohtuvayre$2,100
- XOLAIR$1,780
- AREXVY$1,300
- SMARTVEST$1,200
- Arikayce$252
- OFEV$138
- CHARTIS CATHETER$122
- ZEPHYR DELIVERY CATHETER$122
How this compares
$1,547,264 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 91 | $357,727 |
| Fasenra PenBenralizumab | 56 | $298,575 |
| TezspireTezepelumab-Ekko | 66 | $278,566 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $75,035 |
| NucalaMepolizumab | 17 | $71,324 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 83 | $66,686 |
| Dupixent SyringeDupilumab | 14 | $49,367 |
| Spiriva HandihalerTiotropium Bromide | 70 | $45,803 |
| SymbicortBudesonide/Formoterol Fumarate | 158 | $39,828 |
| Spiriva RespimatTiotropium Bromide | 44 | $31,721 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $18,768 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $8,089 |
| Advair DiskusFluticasone Propion/Salmeterol | 20 | $6,716 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 234 | $6,341 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $5,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $529,529 | $385,079307 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $317,787 | $168,735172 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $9,259 | $39,81060 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in San Antonio
- Antonio AnzuetoSan Antonio$1.8M
- David MarksSan Antonio$453K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Ali AbediSan Antonio$269K
- Napoleon Puente CuellarSan Antonio$208K
- Soma JyothulaSan Antonio$129K
- Anoop NambiarSan Antonio$119K
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.